DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Hirsutism and hypertrichosis

Essential points for quick revision.

Synopsis

Separate androgen-dependent terminal hair from generalised excess growth, detect virilising disease promptly, investigate endocrine or medicine causes proportionately, and offer safe physical and medical hair reduction.

  • Hirsutism means coarse terminal hair in androgen-dependent sites such as chin, upper lip, chest, lower abdomen and back; hypertrichosis is excess hair outside that sexual distribution.
  • Ask what has changed from the person's baseline and what removal methods conceal. Hair density varies normally by family and ancestry, so a visual score is not a universal disease threshold.
  • Slowly progressive hirsutism with irregular cycles, acne or metabolic features commonly reflects PCOS, but normal cycles and hormones can coexist with idiopathic follicular androgen sensitivity.

Key red flags

Rapid progression over months, deepening voice, clitoromegaly, increased muscle bulk, temporal scalp recession, severe biochemical androgen excess or new postmenopausal hirsutism requires urgent endocrine and gynaecological or adrenal localisation.

Virilisation

Deep voice, clitoral enlargement, rapid temporal recession, increased muscle bulk or reduced breast tissue indicates androgen effect beyond ordinary hirsutism.

Investigation priorities

01
Total testosterone by validated assayFirst step

Confirm biochemical androgen excess and identify a result requiring faster specialist localisation.

Management branches

Slow hirsutismDefine androgen context and personal goals

Terminal hair has increased gradually without virilisation or a severe systemic feature.

  1. Document tempo, cycles, pregnancy goals, acne, scalp loss, medicines, supplements, family pattern and removal methods, then examine hair distribution, blood pressure and metabolic or Cushing features.
  2. Measure validated testosterone and SHBG and select pregnancy, thyroid, prolactin or 17-hydroxyprogesterone tests from the phenotype; complete a PCOS assessment when supported.

Key medicines

Eflornithine 11.5% facial creamApply a thin layer to clean dry affected facial skin twice daily at least eight hours apart; wait at least five minutes after hair removal and do not wash the treated area for four hours.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom